Studies showed that GLP-1 receptor agonists like semaglutide are associated with a high proportion of lean muscle loss, which can range from 25% to 40% of the total weight reduction in patients with obesity
Tirzepatide, used in Zepbound and Mounjaro, targets both the GLP-1 and the GIP receptor agonist, while semaglutide, found in Wegovy and Ozempic, mimics only the GLP-1 receptor agonist, a type of hormone in the body that impacts everything from the brain to muscle to the pancreas, stomach and liver
Alterations of Gut Microbiota in IBS Human microbiota comprises trillions of microorganisms, most of which coexist in the gastrointestinal tract (Krautkramer et al., 2021)
Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies
Joseph ensures each patient receives a personalized plan designed for safe, effective, and sustainable results
The data anticipated from these trials will form the definitive evidence base required for regulatory review and clinical guideline development
